Taysha Gene Therapies (TSHA) Current Assets (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Current Assets data on file, last reported at $282.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 133.83% year-over-year to $282.2 million; the trailing twelve-month figure through Mar 2026 stood at $282.2 million (up 133.83% YoY), and the FY2025 full-year result was $324.6 million, up 128.42% from the prior year.
• Current Assets eased to $282.2 million in Q1 2026, from $324.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $324.6 million in Q4 2025 to a low of $43.0 million in Q3 2022.
• A 5-year average of $160.5 million and a median of $142.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 78.19% in 2022 and jumped 299.53% in 2023, its largest moves.
• Tracing TSHA's Current Assets over 5 years: stood at $96.4 million in 2022, then jumped by 55.44% to $149.9 million in 2023, then dropped by 5.16% to $142.1 million in 2024, then jumped by 128.42% to $324.6 million in 2025, then dropped by 13.06% to $282.2 million in 2026.
• Business Quant data shows TSHA's Current Assets at $282.2 million in Q1 2026, $324.6 million in Q4 2025, and $300.0 million in Q3 2025.